Acceleron Pharma Inc
XLRNDelisted Nov 22, 2021- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001280600
Acceleron Pharma Inc was delisted on Nov 22, 2021; its insiders filed their last Form 4 on Nov 22, 2021; 333 institutions reported holding it in 13F filings for Q3 2021, worth $9.22B in total; no superinvestor held it.
Key figures
- Market cap
- –
- Not available
- Insider buys
- 0
- Open market, last 90 days
- Insider sells
- 0
- Open market, last 90 days
- 13F holders
- 333
- Q3 2021, +64 vs. previous quarter
- 13F value
- $9.22B
- Reported value at the end of Q3 2021
- Superinvestors holding
- 0
- At the end of Q3 2021
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2020
- $92.5M
- +25.0% year over year
- Net income, FY2020
- -$166.0M
- No comparable prior period
- Free cash flow, FY2020
- -$134.5M
- No comparable prior period
- Revenue, Q3 FY2021
- $34.2M
- +51.6% year over year
Revenue flow, FY2020
Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue.
Net loss for FY2020: $166.0M (179.4% of revenue).
Superinvestors holding XLRN, Q3 2021
Go to the superinvestors tabNo superinvestor reported holding XLRN at the end of Q3 2021.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Acceleron Pharma Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 27, 2021 (view filing) | Sep 27 | Same day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $175.00 | −$875.0K | −21.3%18.5K after | |
| Sep 24, 2021 (view filing) | Sep 23-24 | 1 day | McLaughlin Kevin FSVP, CFO and Treasurer | SSale | −25.0K | $160.33 | −$4.01M | −70.1%10.7K after | 3 lots |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −6.65K | $150.05 | −$997.8K | −26.0%18.9K after | |
| Sep 22, 2021 (view filing) | Sep 21 | 1 day | Kango SujayEVP, Chief Commercial Officer | SSale | −5.00K | $150.03 | −$750.1K | −21.3%18.5K after | |
| Sep 9, 2021 (view filing) | Sep 8-9 | 1 day | Veness Adam MSVP, General Counsel and Sec. | SSale | −1.41K | $130.00 | −$183.7K | −6.9%18.9K after | 2 lots |
| Jul 2, 2021 (view filing) | Jul 1-2 | 1 day | Dable Habib JCEO and President | SSale | −100.0K | $126.83 | −$12.7M | −50.4%98.5K after | 8 lots |
Top 10 13F holders, Q3 2021
See all 333 holdersThe largest institutional positions in Acceleron Pharma Inc at the end of Q3 2021; share changes are against Q2 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Price T Rowe Associates Inc | 5,365,133 | $923.3M | 0.09% | +65,321+1.2% | Added |
| Vanguard Group Inc | 4,925,189 | $847.6M | 0.02% | +14,836+0.3% | Added |
| Avoro Capital Advisors LLC | 4,000,000 | $688.4M | 10.82% | +1,000,000+33.3% | Added |
| BlackRock Inc. | 3,972,924 | $683.7M | 0.02% | −430,301−9.8% | Reduced |
| Farallon Capital Management, L.L.C. | 2,164,663 | $372.5M | 2.00% | −335,337−13.4% | Reduced |
| FMR LLC | 2,072,735 | $356.7M | 0.03% | −731,204−26.1% | Reduced |
| Darwin Global Management, Ltd. | 2,000,000 | $344.2M | 63.36% | +239,654+13.6% | Added |
| Janus Henderson Group PLC | 1,593,352 | $274.2M | 0.12% | −208,470−11.6% | Reduced |
| Bamco Inc | 1,292,998 | $222.5M | 0.51% | −9,277−0.7% | Reduced |
| Alkeon Capital Management LLC | 1,245,412 | $214.3M | 0.72% | −2,719−0.2% | Reduced |